Xencor (NASDAQ:XNCR) Given New $42.00 Price Target at Cantor Fitzgerald

Xencor (NASDAQ:XNCR) had its price objective hoisted by analysts at Cantor Fitzgerald from $40.00 to $42.00 in a research report issued on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 179.93% from the company’s current price.

A number of other research analysts also recently commented on XNCR. Barclays raised shares of Xencor from an “underweight” rating to an “overweight” rating and upped their price objective for the company from $6.00 to $23.00 in a research note on Wednesday, October 29th. Wells Fargo & Company lowered their target price on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research note on Tuesday, October 14th. Bank of America lowered shares of Xencor from a “buy” rating to a “neutral” rating and decreased their price target for the company from $23.00 to $12.00 in a report on Wednesday, September 3rd. Finally, Royal Bank Of Canada upped their price objective on Xencor from $15.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Xencor Trading Up 4.4%

Shares of Xencor stock traded up $0.63 during trading hours on Thursday, reaching $15.00. 42,933 shares of the company’s stock were exchanged, compared to its average volume of 877,026. Xencor has a 52-week low of $6.92 and a 52-week high of $27.24. The company has a fifty day moving average of $11.47 and a 200-day moving average of $9.64. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -6.25 and a beta of 0.99.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.64. The business had revenue of $21.00 million during the quarter, compared to the consensus estimate of $29.73 million. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.71) earnings per share. On average, equities research analysts anticipate that Xencor will post -3.68 earnings per share for the current fiscal year.

Institutional Trading of Xencor

Institutional investors have recently added to or reduced their stakes in the business. New York State Teachers Retirement System raised its position in Xencor by 2.1% in the first quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company’s stock valued at $631,000 after purchasing an additional 1,200 shares during the period. Principal Financial Group Inc. grew its stake in shares of Xencor by 2.5% in the first quarter. Principal Financial Group Inc. now owns 348,726 shares of the biopharmaceutical company’s stock valued at $3,710,000 after buying an additional 8,581 shares in the last quarter. CWM LLC raised its holdings in shares of Xencor by 195.5% during the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 2,231 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Xencor during the 1st quarter worth approximately $528,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Xencor in the 1st quarter worth approximately $135,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.